These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 30715571

  • 1. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization.
    Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, Bouvry C, Le Sourd S, Pracht M, Ardisson V, Noiret N, Bellissant É, Garin E.
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1506-1517. PubMed ID: 30715571
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma.
    Garin E, Denizot B, Noiret N, Lepareur N, Roux J, Moreau M, Herry JY, Bourguet P, Benoit JP, Lejeune JJ.
    Nucl Med Commun; 2004 Oct; 25(10):1007-13. PubMed ID: 15381868
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, Dierckx RA, Van de Wiele C, Thierens H, De Vos F.
    J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model.
    Paeng JC, Jeong JM, Yoon CJ, Lee YS, Suh YG, Chung JW, Park JH, Chung JK, Son M, Lee MC.
    J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
    Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C.
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A comparison of three transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans.
    Yu SC, Leung TW, Lau WY, Lee N, Hui EP, Yeo W, Lai PB, Mok TS.
    Cardiovasc Intervent Radiol; 2008 Mar; 31(2):289-98. PubMed ID: 17926090
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study.
    Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ.
    Arch Surg; 2000 Nov; 135(11):1298-300. PubMed ID: 11074884
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 131I-Lipiodol delivery on tumour uptake and response.
    Brans B, Bacher K, Vandevyver V, Vanlangenhove P, Smeets P, Thierens H, Dierckx RA, Defreyne L.
    Nucl Med Commun; 2003 Apr; 24(4):391-6. PubMed ID: 12673167
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.